ストックスクリーナーアプリを入手
0.00
100.00%
-0.0941
Palatin Technologies Inc. (PTN) 最新ニュース
Palatin Technologies Q1 Net Loss Narrows On Lower Expenses - Nasdaq
Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update - PR Newswire
Palatin Technologies (PTN) to Release Quarterly Earnings on Wednesday - Defense World
Palatin Technologies (NYSE:PTN) Coverage Initiated by Analysts at StockNews.com - Defense World
Palatin Technologies director Robert DeVeer buys $10,180 in stock By Investing.com - Investing.com India
Palatin Technologies director Robert DeVeer buys $10,180 in stock - Investing.com
Palatin reveals potential diabetic retinopathy treatments - Investing.com
Palatin reveals potential diabetic retinopathy treatments By Investing.com - Investing.com India
Palatin Unveils Promising Preclinical Data For Diabetic Retinopathy Treatments At ARVO 2025 - Nasdaq
Palatin Technologies Announces Closing of Reduced Public Offerin - GuruFocus
Two new option listings and two option delistings on May 9th - TipRanks
Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025 - GuruFocus
Palatin expects $11.5M financing to cure NYSE American delisting notice - MSN
Palatin Technologies Announces Closing of Reduced Public Offering - Morningstar
Palatin Technologies Announces Closing of Reduced Public Offering | PTN Stock News - GuruFocus
Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025 - The Malaysian Reserve
Palatin Technologies (PTN) Reveals Promising Phase 3 Study Results for PL9643 in Dry Eye Disease | PTN Stock News - GuruFocus
Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025 | PTN Stock News - GuruFocus
PTN Faces Delisting from NYSE American, Shares Transition to OTC Market | PTN Stock News - GuruFocus
Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice - Lelezard
Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice | PTN Stock News - GuruFocus
Palatin Technologies faces delisting from NYSE American due to low stock price - Investing.com Canada
NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN) - Business Wire
Palatin secures $11.5 million to tackle NYSE delisting, boost obesity drugs - Investing.com Australia
Palatin Technologies sets terms for $23 million offering By Investing.com - Investing.com South Africa
Palatin secures $11.5 million to tackle NYSE delisting, boost obesity drugs By Investing.com - Investing.com South Africa
Palatin Prices $11.5 Mln Public Offering - Nasdaq
Palatin Expects $11.5 Mln Offering To Aid NYSE Compliance And Fuel Obesity Drug Development - Nasdaq
Palatin (PTN) Aims to Address Delisting Concerns with Public Off - GuruFocus
Palatin Technologies Stock Trading Halted Pending Material Announcement - marketscreener.com
Palatin Expects $11.5 Million Financing to Cure NYSE American De - GuruFocus
Palatin Expects $11.5 Million Financing - citybiz
Palatin Technologies Announces Pricing Of Up To $23 Million Public Offering - marketscreener.com
Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice - GuruFocus
Palatin Technologies Announces Pricing of up to $23 Million Public Offering - StreetInsider
Palatin Technologies Announces Pricing of up to $23 Million Public Offering | PTN Stock News - GuruFocus
Palatin Technologies sets terms for $23 million offering - Investing.com
Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice – Company Announcement - Financial Times
Palatin (PTN) Unveils Promising Data for Glaucoma Treatment Cand - GuruFocus
Palatin Presents Promising Preclinical Data for Melanocortin Ago - GuruFocus
Palatin Technologies Announces Encouraging Pre-Clinical Data Of PL9588 For Glaucoma Treatment - Nasdaq
Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy - GuruFocus
Palatin (PTN) Unveils Promising Data for Glaucoma Treatment Candidate PL9588 | PTN Stock News - GuruFocus
Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy – Company AnnouncementFT.com - Financial Times
Palatin Technologies (NYSE:PTN) Coverage Initiated at StockNews.com - Defense World
After The Stock Rose 2.56% Over The Week, Is Palatin Technologies Inc (AMEX: PTN) Still A Buy? - Marketing Sentinel
Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease - The Malaysian Reserve
Palatin Announces Breakthrough Symptom Resolution in Updated Ana - GuruFocus
Palatin (PTN) Announces Promising Results for PL9643 in Dry Eye Disease Study | PTN Stock News - GuruFocus
Palatin Reports Positive Results From Responder Analyses Of Phase 3 MELODY-1 Study In DED - Nasdaq
0.43%
大文字化:
|
ボリューム (24 時間):